Covington represented the underwriters on the deal.Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced…
Marinus Pharmaceuticals’ $60 Million Public Offering
